

TRANSFUSION REACTION REPORT- THE RECIPIENT

OCTOBER 2015
VERSION 1

CODE: LCBT-HV FIT 002

DOCUMENT OF TRANSFUSION-RELATED ACTIVITIES

Sheet number

--	--	--

Code of establishment

--	--

army

--	--	--

Order number

RECIPIENT TRANSFUSION REACTION REPORT

1. PATIENT INFORMATION

1.1 - Date of birth: /..... /..... 1. 2- Gender: Male Female

1.3 – History:

Pregnancy, miscarriage Yes No

Previous transfusions Yes No

History of Alloimmunization Yes No

Previous transfusion reaction Yes No

If Yes: sheet number.....

1.4 - Indications for transfusion:

1.5 – Place of transfusion: Surgery Medicine Gynecology other.....

2. ORDER OF EVENTS

2.1- Transfusion: Date started /..... /..... Time started..... Hr..... min

2.2 – Adverse reaction: Date of occurrence /..... /..... Time of occurrence..... Hr..... min

2.3 - Date of informing the Hemovigilance officer: /..... /..... Date of documentation /..... /.....

3. MANIFESTATIONS

3.1 – Clinical manifestations :

Pre-transfusion temperature: °C Temperature during reaction : °C

Pre-transfusion blood pressure: .../..... mmHg BP during reaction : .../..... mmHg

Pre-transfusion heart rate b/min HR during reaction b/min

<input type="checkbox"/> Shock <input type="checkbox"/> Chills <input type="checkbox"/> Pain	<input type="checkbox"/> Cough <input type="checkbox"/> Dyspnea <input type="checkbox"/> Bronchospasm <input type="checkbox"/> Pulmonary edema	<input type="checkbox"/> Nausea <input type="checkbox"/> Vomiting <input type="checkbox"/> Diarrhea	<input type="checkbox"/> Pruritus <input type="checkbox"/> Urticaria <input type="checkbox"/> Erythema <input type="checkbox"/> Angioedema
<input type="checkbox"/> Other clinical manifestations : 1. 2.			

3.2 –Laboratory results:

<p>Hemoglobin Pre-transfusion : ..., g/dL Post-transfusion : ..., g/dL</p> <p>Platelets Pre-transfusion : G/L Post-transfusion : G/L</p>	<ul style="list-style-type: none"> • Direct Coombs positive <input type="checkbox"/> yes <input type="checkbox"/> No • Hemoglobinuria <input type="checkbox"/> yes <input type="checkbox"/> No • Appearance of alloantibodies <input type="checkbox"/> yes <input type="checkbox"/> No • Haptoglobin level..... • Viral marker positivity <input type="checkbox"/> yes <input type="checkbox"/> No <p>If yes, specify:</p> <p>Others</p>
--	---

4- ADVERSE REACTION SEVERITY

0

1

2

3

4

0: no clinical or laboratory manifestations

1: not severe

2: severe

3: imminent vital risk

4: death

5- DIAGNOSTIC ORIENTATION(S)

Considered diagnosisCode according to AR list:

Certainty of diagnosis: Possible Probable Certain N/A

6 – DELIVERY AND PRE-TRANSFUSION QUALITY CONTROL

6.1 – Delivered by

BTS of ME BTS of other establishments..... Code of establishment:

Life Saving yes no

6.2 – **Bedside** pre-transfusion dual check and verification of patient's identity / blood group / documents and concerned blood product : yes no

6.3 – Bed side control performed by two people : yes no

Concordance between identity/group/patient/documents and product yes no

ABO compatibility for PRBCs yes no

Correct Techniques and interpretation yes no

7- TRANSFUSION TYPE

Allogeneic

Autologous

7.1 – Blood products used during implicated transfusion reaction.

Timetable of the Transfusions	Denomination of Product (Code and qualifications)	TR
1		
2		
3		
4		
5		
6		

For transfusion reaction incriminated products: Sampling date:/...../..... Donor sex M F

Time transfusion started: H mn

7.2 – Preventive measures yes no If yes:

Adverse reactions with potential risk for other recipients: yes No not known

7.3 – Suspicion of defective material yes no

8- INVESTIGATIONS AND CONCLUSION

8.1 – Further investigations

Microbiology :

• Blood culture: Patient/product: ongoing not done negative result positive result

If patient culture positive: Bacterial identification Responsible for reaction Contamination

If product culture positive Bacterial identification..... Responsible for reaction Contamination

Hematological investigations: ABO/Rh1 Patient: ABO/ Rh1 product:
 Pre-transfusion irregular Antibodies:.....Post-transfusion irregular antibodies:.....
 Other investigations cite:.....

Other explorations:

.....

8.2 – Imputability:

Not evaluated (NE) improbable - excluded (0) Possible (1) Probable (2) Certain (3)
 Concomitant disease that could explain the adverse effect:

8.3 – Final remarks and conclusions from Hemovigilance correspondents

.....

.....

.....

8.4 – Investigations

State of investigation: Ongoing Finished Not realized
 Patient outcome : Complete remission Minor sequela Severe sequela Death

8.5 - Signature of correspondents

Hospital Site:

Date:/...../.....

Name - Surname:

Phone:

Qualification: Titular Designee

Distribution Site:

Date:/...../.....

Name - Surname

Phone:

Qualification: Titular Designee

An approved copy of this report must be kept in the patient's chart.

In addition, the distribution center of blood products and the medical center must keep copies of this report.

BTS : Blood transfusion center

LBP : Labile blood products

BPDC : blood products distribution center